Nestle India reported a 27.18 per cent Y-o-Y rise in consolidated net profit at ₹1,110.9 crore for March quarter, boosted by ...

Sidetrade (Euronext Growth: ALBFR.PA), the AI-native Order-to-Cash platform recognized as a Leader in the Gartner® Magic Quadrant™, unveils “O2C Intelligence 2030,” a four-year strategic plan that ...

Sculptural lines and mixed materials make these workhorse pieces both practical and cool. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de ...

Imagine this: Your business agrees to sell products to a distributor. You spend to produce the goods, but poor communication between your order fulfillment operations and shipping and billing ...

Although the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have soared in recent years, things may not be as rosy for Wall Street as these indexes suggest. The Iran war may bring the Fed ...

MAYFIELD, Ohio -- Some Mayfield City Schools students are experiencing the satisfaction of having the fruits (or in this case the lettuce) of their classroom efforts result in a real-life application ...

GENEVA (AP) — Delegations from Moscow and Kyiv met in Geneva on Tuesday for another round of U.S.-brokered peace talks, a week before the fourth anniversary of Russia's full-scale invasion of its ...

Gianandrea Noseda will conduct a complete Ring cycle at Carnegie Hall in the 2026-27 season. Photo: Stefano Pasqualetti Carnegie Hall’s 2026-2027 schedule promises some of the most substantial and out ...

Analyst Insight: Many biotech firms struggle to manage the order-to-cash (O2C) cycle effectively because large contract manufacturers (CMOs) often handle physical shipping, while the firm retains ...

This week’s issue of Cycle News magazine includes our 2025 Rider of the Year, Marc Marquez, who is featured on the cover of our extra-big year-end issue, which is packed with features to keep you busy ...

Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.